Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Indinavir (IDV; trade name Crixivan, made by Merck) is a protease inhibitor used as a component of highly active antiretroviral therapy to treat HIV/AIDS. It is soluble white powder administered orally in combination with other antiviral drugs. The drug prevents protease from functioning normally. Consequently, HIV viruses cannot reproduce, causing a…
History, Applications & Companies
Explore the main themes, entities and connections around Indinavir. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
drug protease hiv drugs viral aids merck treatment one patients users virus azt study research used load development lamivudine people
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Indinavir | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Indinavir | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Indinavir | ATC code | J05AE02 (WHO) | 1.00 | infobox |
| Indinavir | Bioavailability | ~65% | 1.00 | infobox |
| Indinavir | CAS Number | 150378-17-9 Y | 1.00 | infobox |
| Indinavir | ChEBI | CHEBI:44032 Y | 1.00 | infobox |
| Indinavir | ChEMBL | ChEMBL540914 N | 1.00 | infobox |
| Indinavir | ChemSpider | 4515036 Y | 1.00 | infobox |
| Indinavir | CompTox Dashboard (EPA) | DTXSID4043802 | 1.00 | infobox |
| Indinavir | DrugBank | DB00224 Y | 1.00 | infobox |
| Indinavir | Elimination half-life | 1.8 ± 0.4 hours | 1.00 | infobox |
| Indinavir | Formula | C36H47N5O4 | 1.00 | infobox |
| Indinavir | KEGG | C07051 Y | 1.00 | infobox |
| Indinavir | License data | US FDA: Indinavir | 1.00 | infobox |
| Indinavir | MedlinePlus | a696028 | 1.00 | infobox |
| Indinavir | Metabolism | Hepatic via CYP3A4 | 1.00 | infobox |
| Indinavir | Molar mass | 613.803 g·mol−1 | 1.00 | infobox |
| Indinavir | NIAID ChemDB | 005824 | 1.00 | infobox |
| Indinavir | PDB ligand | MK1 (PDBe, RCSB PDB) | 1.00 | infobox |
| Indinavir | Protein binding | 60% | 1.00 | infobox |
| Indinavir | PubChem CID | 5362440 | 1.00 | infobox |
| Indinavir | Routes of administration | Oral | 1.00 | infobox |
| Indinavir | Trade names | Crixivan | 1.00 | infobox |
| Indinavir | UNII | 9MG78X43ZT | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.